Solorank.ai
Cached score snapshot
US.EW · Edwards Lifesciences
110分制 60.3/110；5D動能v2 8/50；排序分 68.3/160
Score breakdown
觀望
Score and price trend
Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.
Move the mouse over the chart lines to inspect readings.
- Main score
- 5D momentum v2
- Candlestick
- Historical projection
- Score turn
- Setup grade
| Model | Median | P25/P75 | 歷史相似情境上漲比例 | Down5 | Actual / compare |
|---|---|---|---|---|---|
| Rolling DOE best | +0.68% | -1.00% / +3.22% | 65% | 0% | Actual outcome pending · 0 / 3 bars observed |
| 30D observation | -0.71% | -2.51% / +2.91% | 45% | 15% | Actual outcome pending · 0 / 30 bars observed |
| Historical projection 10D n=160 | +0.64% | -1.47% / +2.48% | 60% | 1.9% | Actual outcome pending · 0 / 10 bars observed |
歷史情境統計基於已存檔相似 setup；圖中投影中位線為統計中位數的線性插值展示，並非價格路徑預測或買賣建議。
2026-08-03 → 2026-12-07 · 120 archived points · 1 Improving turn signal · 6 Deteriorating signal
Summary
score_with_momentum_v2 = main score + 5D momentum v2
Ranking score
68.3
Display grade
觀望
Model version
cursor_18_27_news_v2_160
Main score
60.3/110 (觀望)
5D momentum v2
8/50 (弱)
Score with momentum v2
68.3/160 (低排序)
Risk level
Medium
Rolling setup rating
Setup quality, historical edge, and risk are combined into a rolling S/A/B/C/D/F grade for this snapshot date.
Score turn monitor
Has the score quality changed?
Run more market refreshes to build enough archived points for a turn check.
Signals
技術信號 20 · 資金流 15.6 · 5D動能v2 8
INSTITUTIONAL_DATA_OPTIONAL: Institutional ownership unavailable; neutral money-flow treatment used. FMP_INSTITUTIONAL_FAILED: FMP HTTP 402
Audit trace
Full calculation detail
Calculation detail · 8 sections
Market inputs
Bar count
60
ma20
87.006
ma50
88.0398
close
90.56
prevClose
89.07
avgVolume20
3542064
volumeRatio
0.94
changePercent
1.67
Metrics snapshot
close
90.56
volume
3326578
changePercent
1.67
110-point main rating
基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10
Main score
60.3/110
Main rating
觀望
5D momentum v2
8/50
Score with momentum v2
68.3/160
Formula
score_with_momentum_v2 = main_score + momentum_5d_v2_score
基本面 — 2.7/5 · 較差
Dimension score
2.7/5
Dimension grade
較差
Sub-items
pbPoints
0.2
pePoints
0.2
epsPoints
0
roePoints
0
debtPoints
0.5
marginPoints
0.4
turnoverUsdM
301.2549
volumePoints
0.5
revenuePoints
0.4
dividendPoints
0
marketCapPoints
0.5
資金流 — 15.6/20 · 良好
Dimension score
15.6/20
Dimension grade
良好
Sub-items
cmfPoints
2.4
mfiPoints
3.2
obvPoints
4
vwapPoints
4
institutional
score
2
details
source
optional-neutral
warning
code
INSTITUTIONAL_DATA_OPTIONAL
symbol
US.EW
message
Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional
true
holderCount
n/a
holderPoints
2
top10ShareRatio
n/a
concentrationPenalty
0
institutionPoints
2
市場環境 — 6.4/15 · 較差
Dimension score
6.4/15
Dimension grade
較差
Sub-items
vix
score
1.8
details
source
twelvedata+fred
vixClose
19.45
trend
score
0.8
details
qqq
ma20
734.0185
ma50
725.4348
name
QQQ
close
712.2
points
0.4
spy
ma20
770.1385
ma50
767.589
name
SPY
close
765.37
points
0.4
source
twelvedata+fred
atrPct
2.2261
atrPoints
3
cciPoints
0.8
vixPoints
1.8
marketTrendPoints
0.8
催化劑 — 2/20 · 較差
Dimension score
2/20
Dimension grade
較差
Sub-items
catalyst
score
2
details
source
finnhub_news_keyword_model
articleCount
2
catalystCount
0
catalystPoints
2
風險管理 — 7.6/10 · 良好
Dimension score
7.6/10
Dimension grade
良好
Sub-items
position
score
1.6
details
atrPct
2.2261
turnoverUsdM
301.2549
liquidityPoints
0.6
volatilityPoints
1
rrPoints
1.6
stopLevels
symbol
US.EW
rr_range
1:1.0-1:2.5
risk_profile
中等
stop_loss_price
86.528
strength_details
ma_score
1
atr_score
2
rsi_score
3
macd_score
3
volume_score
1
market_adjustment
1
risk_reward_ratio
1.5
stop_loss_percent
4.5
take_profit_price
96.6214
target_multiplier
2.2
technical_strength
2.05
take_profit_percent
6.7
positionPoints
1.6
stopLossPoints
2.4
diversification
score
2
details
method
sector concentration proxy; no portfolio holdings used
sector
Health Care
concentratedSectorPenalty
0
riskRewardRatio
1.5048
stopLossPercent
4.4523
diversificationPoints
2
技術信號 — 20/30 · 一般
Dimension score
20/30
Dimension grade
一般
Sub-items
bbPoints
3
adxPoints
3
sarPoints
2.4
vcpPoints
0.9
macdPoints
4
vcpPayload
vcp_pass
false
vcp_score
0.9
vcp_reason
站上MA50；升放量(近10日2日)；Ready=N；Confirm=Y
vcp_metrics
up_days
6
vol_ref
3620926.6667
down_days
3
vcp_ready
false
above_ma50
true
avg_vol_10
3312480
avg_vol_20
3537140
avg_vol_30
3620926.6667
range_pct_10
0.0718
range_pct_20
0.0952
range_pct_30
0.0952
up_expand_ok
true
lookback_used
59
near_20d_high
true
contraction_ok
false
down_shrink_ok
false
up_expand_days
2
breakout_20d_ok
false
vol_ratio_10_30
0.9148
dist_to_20d_high
0.0054
down_shrink_days
1
breakout_level_20d
91.05
vcp_breakout_confirm
true
contraction_ratio_10_30
0.7541
vcp_name_en
Volatility Contraction Pattern
vcp_name_zh
波動收縮形態
vol_contraction
false
kdjAdxPoints
0.7
rsiKdjPoints
4
volumeWeight
2
maCrossPoints
0
shortRsiPoints
0.8
shortMacdPoints
0.4
volConfirmPoints
0
volumePointsTechnical
0.8
情緒分析 — 6/10 · 一般
Dimension score
6/10
Dimension grade
一般
Sub-items
sentiment
score
6
details
source
finnhub_news_keyword_model
articleCount
2
negativeHits
0
positiveHits
1
sentimentScoreRaw
1.2
sentimentData
raw
{"id":143132433,"url":"https://finnhub.io/api/news?id=b913cc1f116b22cc2be45e9b6bd9d7b38f17ecce5afdecf6450e60f48867bf84","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Edwards Lifesciences reported past FDA approvals for its PASCAL Precision system for tricuspid valve repair and PASCAL Ace with Capture Clarity for degenerative mitral TEER, giving the business a broader U.S. transcatheter repair toolkit for patients who are not good candidates for open heart surgery. The combination of tricuspid and mitral TEER approvals makes Edwards Lifesciences the only supplier offering both repair and replacement transcatheter options across these valves in the U.S.,...","category":"company","datetime":1792754284,"headline":"Does Valve Repair Approval Change The Bull Case For Edwards Lifesciences (EW)?"}, {"id":143100621,"url":"https://finnhub.io/api/news?id=a8698f0719f543a45a3043e24bc1b0a6f9596a76ec9c66d43eab7060c8670246","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Edwards Lifesciences' TMTT and TAVR growth, strong clinical evidence and solid balance sheet support expansion, but tariffs and currency headwinds threaten margins.","category":"company","datetime":1792669680,"headline":"Is This the Right Time to Hold EW Stock in Your Portfolio?"}
raw_source
{"id":143135911,"url":"https://finnhub.io/api/news?id=789c5f64f3f2cf7881b4b07392f83e9f63dfedf383c1ea91818187027101ec47","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Inspire Medical Systems gains 47.8% in three months as improved reimbursement clarity, an earnings beat, $30 million in annual savings and new CPT codes boost recovery prospects.","category":"company","datetime":1792766220,"headline":"INSP Stock Gains 47.8% in Three Months: What's Driving the Rally?"}, {"id":143132433,"url":"https://finnhub.io/api/news?id=b913cc1f116b22cc2be45e9b6bd9d7b38f17ecce5afdecf6450e60f48867bf84","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Edwards Lifesciences reported past FDA approvals for its PASCAL Precision system for tricuspid valve repair and PASCAL Ace with Capture Clarity for degenerative mitral TEER, giving the business a broader U.S. transcatheter repair toolkit for patients who are not good candidates for open heart surgery. The combination of tricuspid and mitral TEER approvals makes Edwards Lifesciences the only supplier offering both repair and replacement transcatheter options across these valves in the U.S.,...","category":"company","datetime":1792754284,"headline":"Does Valve Repair Approval Change The Bull Case For Edwards Lifesciences (EW)?"}, {"id":143136778,"url":"https://finnhub.io/api/news?id=5a5d111056252b2999b0ad4b505d9e30cec05621715a58d9d8440adabcce4679","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Edwards’ approval should “strengthen the company’s position in the large and underpenetrated transcatheter tricuspid market,” analysts said.","category":"company","datetime":1792750806,"headline":"Edwards wins FDA approval for tricuspid valve repair device"}, {"id":143103804,"url":"https://finnhub.io/api/news?id=62fd12e5080b12b6263d31d607a9f1b4d07b54f3d1d98dbe99a2fb7960637686","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"DaVita's 55.6% stock rally reflects stronger operating execution, improving treatment volumes and value-based kidney care gains despite reimbursement pressures.","category":"company","datetime":1792690680,"headline":"DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally?"}, {"id":143103803,"url":"https://finnhub.io/api/news?id=64e91c8c6fe34a2c1b6d7ffac246833155002d30dbbbee5bbf17bcba5d08f536","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"BD's 25.5% rally reflects stronger execution, portfolio reshaping, product innovation and U.S. manufacturing investments despite tariffs and cost pressures.","category":"company","datetime":1792689660,"headline":"BDX Stock Gains 25.5% in Six Months: What's Behind the Rally?"}, {"id":143100621,"url":"https://finnhub.io/api/news?id=a8698f0719f543a45a3043e24bc1b0a6f9596a76ec9c66d43eab7060c8670246","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Edwards Lifesciences' TMTT and TAVR growth, strong clinical evidence and solid balance sheet support expansion, but tariffs and currency headwinds threaten margins.","category":"company","datetime":1792669680,"headline":"Is This the Right Time to Hold EW Stock in Your Portfolio?"}, {"id":143094387,"url":"https://finnhub.io/api/news?id=b2c85aa8df922e4873506e30b09daeb9bd72bff0ea48f981feb94a865d6e34f3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"The PASCAL Precision device is indicated to treat individuals with symptomatic severe tricuspid regurgitation.","category":"company","datetime":1792660520,"headline":"Edwards secures FDA approval for tricuspid valve repair system"}, {"id":143067817,"url":"https://finnhub.io/api/news?id=b4575036babe3ca17c3d9b9b280784523ba14d92717883c8b9ffb333608060fd","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"IRVINE, Calif., October 21, 2026--Edwards Lifesciences Corporation (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved its PASCAL Precision system for tricuspid valve repair. The system is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation (TR) despite optimal medical therapy who are deemed at intermediate or greater risk for surgery and deemed appropriate for transcatheter edge-to-edge tr","category":"company","datetime":1792587600,"headline":"FDA Approval of Edwards Lifesciences’ PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease"}, {"id":143067541,"url":"https://finnhub.io/api/news?id=81838d297dff31d72c83688080f0c7fe609014e55d3a8995b53e4433356df155","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"ISRG's Q3 2026 earnings beat estimates as strong system placements, rising procedure volumes and improving margins fuel double-digit revenue growth.","category":"company","datetime":1792585980,"headline":"Intuitive Surgical's Q3 Earnings Beat Estimates on Strong System Sales"}, {"id":143067057,"url":"https://finnhub.io/api/news?id=c52e0234621653156fb737978b4b17fc182b84f9ed2c5c3bcd798f931671d143","image":"https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_2.jpg?width=2048&height=1536","source":"Benzinga","related":"EW","summary":"This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often","category":"company","datetime":1792503310,"headline":"9 Health Care Stocks Whale Activity In Today’s Session"}, {"id":142950181,"url":"https://finnhub.io/api/news?id=96549fc3169af14a5b37e1838856ce6d4ea231da47ab79fb2b1b643ba4673a05","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"The U.S. Food and Drug Administration (FDA) issued a high-risk early alert after Edwards Lifesciences Corp. (NYSE:EW) recalled specific lots of its Commander M delivery systems due to reports of balloons bursting during procedures, resulting in one death and a serious injury. Recall Of Commander M Delivery Systems The delivery systems help implant a replacement mitral heart valve through blood vessels, bypassing the need for open-chest surgery. However, the company received three distinct report","category":"company","datetime":1792163582,"headline":"FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death"}, {"id":142945843,"url":"https://finnhub.io/api/news?id=efc985c8849482b1c5cb63a903feab7a147146983249315764c2b32ff17b12da","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"An issue with the delivery component of Edwards’ SAPIEN M3 TMVR system has been associated with one patient death and one serious injury as of 5 October.","category":"company","datetime":1792151246,"headline":"Edwards’ SAPIEN M3 delivery system linked to patient death in FDA alert"}, {"id":142947552,"url":"https://finnhub.io/api/news?id=cce961828583081443d280e38e71db1b045f33b20765ffc7c43f7023022e5860","image":"","source":"Benzinga","related":"EW","summary":"https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-transcatheter-mitral-valve-delivery-system-issue-edwards-lifesciences ","category":"company","datetime":1792122647,"headline":"Reported Earlier, Edwards Lifesciences Tells Customers To Remove Four Lots Of Commander M Delivery Systems For SAPIEN M3; FDA Flags Potentially High-Risk Issue"}, {"id":142882630,"url":"https://finnhub.io/api/news?id=5e4289c0c9b96dfa1e95a00694f6be0915f8672c2b831308bed3a3fce09f0551","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"With the US population aging rapidly, three healthcare ETFs offer exposure to companies developing treatments, drugs and medical devices for age-related conditions.","category":"company","datetime":1791979740,"headline":"Bet on These Healthcare ETFs to Benefit From the Aging US Population"}, {"id":142821843,"url":"https://finnhub.io/api/news?id=5b892fbff9720a6bd56b824deb05c3dc8dcd697cd77783988b10fb0eaab315fb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Edwards Lifesciences is set to report its Q3 earnings next month, with analysts expecting single-digit year-over-year EPS growth.","category":"company","datetime":1791795397,"headline":"Edwards Lifesciences Earnings Preview: What to Expect"}, {"id":142730419,"url":"https://finnhub.io/api/news?id=5741fde32d2d428cfb091510e2b9dc970e9a9cdc9798a0a9de13df26fb600389","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"EW","summary":"Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.","category":"company","datetime":1791477301,"headline":"Stay informed with the top movers within the S&P500 index on Thursday."}, {"id":142703057,"url":"https://finnhub.io/api/news?id=cbb9c770540f123bf7f8169895da328689f42faa5286fda4eeaa46990dd6c523","image":"","source":"Fintel","related":"EW","summary":"","category":"company","datetime":1791417130,"headline":"Barclays Initiates Coverage of Edwards Lifesciences at Overweight"}, {"id":142699429,"url":"https://finnhub.io/api/news?id=c7662009b9ace98cff37eb649fd5c094fe1d8023fc1a1ff779048499c9832520","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Intuitive Surgical SP platform is gaining momentum as procedures, utilization and placements rise, with expanding indications and global adoption fueling growth.","category":"company","datetime":1791394260,"headline":"Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise?"}, {"id":140420211,"url":"https://finnhub.io/api/news?id=c9045c53ac19ad80d94a07c2e8320fa134ac76c18ad5824d79898864952688d5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Intel downgraded, Marvell upgraded: Wall Street's top analyst calls","category":"company","datetime":1791381613,"headline":"Intel downgraded, Marvell upgraded: Wall Street's top analyst calls"}, {"id":142689571,"url":"https://finnhub.io/api/news?id=7328d68ff960ea6cd6cc1d7e84ad93210c84e804ca09c005e1de805c1458a6df","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"IRVINE, Calif., October 07, 2026--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended Sept. 30, 2026 after the market closes on Wednesday, Nov. 4, and will host a conference call at 5:00 p.m. ET that day to discuss those results.","category":"company","datetime":1791367200,"headline":"Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026"}, {"id":142696722,"url":"https://finnhub.io/api/news?id=b571dd0f7ba78a624d470fa3b3093c847514e128ce54822d2c1d0f3490f79271","image":"","source":"Benzinga","related":"EW","summary":"Barclays analyst Christopher Pasquale initiates coverage on Edwards Lifesciences (NYSE:EW) with a Overweight rating and announces Price Target of $110.","category":"company","datetime":1791362408,"headline":"Barclays Initiates Coverage On Edwards Lifesciences with Overweight Rating, Announces Price Target of $110"}, {"id":142632289,"url":"https://finnhub.io/api/news?id=5e79a351c69253cee95dc15b7a09a3b5363e19ef80d37e125eab80d72c621996","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"IRVINE, Calif., October 05, 2026--Edwards Lifesciences (NYSE: EW) today announced that it will host an investor event in conjunction with the TCT annual scientific symposium in San Diego on Monday, Nov. 2, from 5:00 to 6:00 PM Pacific Time. The meeting will include a live Q&A session with physicians and members of the Edwards management team.","category":"company","datetime":1791194400,"headline":"Edwards Lifesciences to Host Investor Event in Conjunction With TCT"}, {"id":142614627,"url":"https://finnhub.io/api/news?id=8655f8ec1bb477449776d78501af9ab82fe6b743d6ab33f1f8d7997fe0bbe8ef","image":"https://cdn.benzinga.com/files/images/story/2026/10/02/Doctors--Tablet-And-People-With-Discussi.jpg?width=2048&height=1536","source":"Benzinga","related":"EW","summary":"Edwards Lifesciences earned FDA approval for its AUTUS pediatric heart valve, designed to expand as young patients grow.","category":"company","datetime":1790937962,"headline":"Edwards Lifesciences Secures FDA Approval for First Expandable Pediatric Heart Valve"}, {"id":142589114,"url":"https://finnhub.io/api/news?id=80eebecc20b73e3685f3c3092f41f338a5253af972377b06c0dc5ce304802ac8","image":"https://cdn.benzinga.com/files/images/story/2026/10/02/Bangkok--Thailand---July-2--2017nike-Cla.jpg?width=2048&height=1536","source":"Benzinga","related":"EW","summary":"Nike falls on weak revenue; Synaptics jumps on $123 ON deal; AsiaStrategy surges on tokenization pact; Mangoceuticals drops.","category":"company","datetime":1790914563,"headline":"Nike, Synaptics And 3 Stocks To Watch Heading Into Friday"}, {"id":142563009,"url":"https://finnhub.io/api/news?id=b0ab83642594294ce72c45514fe4296905c2602deb7307b9dddd9eaf37adf90a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"IRVINE, Calif., October 01, 2026--Edwards Lifesciences (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease who require pulmonary valve replacement.","category":"company","datetime":1790886360,"headline":"Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients"}, {"id":142590120,"url":"https://finnhub.io/api/news?id=17619dfabefb34c722fa720a4545f003a4542ab1a2e12bc371a4dd0e88326aff","image":"","source":"Benzinga","related":"EW","summary":"Edwards Lifesciences (NYSE:EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with","category":"company","datetime":1790872027,"headline":"Edwards Lifesciences Says FDA Approves AUTUS Size-Adjustable Valve, Surgical Pulmonary Valve Designed For Pediatric Patients With Congenital Heart Disease"}
data_source
finnhub_news_keyword_model
article_count
2
negative_hits
0
positive_hits
1
recomputed_at_score
true
sentiment_score_raw
1.2
source_article_count
26
discarded_article_count
24
sentimentPoints
6
Dimension contribution
Dimension
Raw
Max
Norm %
Contrib
基本面
2.7
5/110
54%
2.7
資金流
15.6
20/110
78%
15.6
市場環境
6.4
15/110
42.67%
6.4
催化劑
2
20/110
10%
2
風險管理
7.6
10/110
76%
7.6
技術信號
20
30/110
66.67%
20
情緒分析
6
10/110
60%
6
5D momentum v2 breakdown
Cursor_18.25 5D momentum v2 0-50
5D momentum v2
8/50
ret_5d
0.0383
max_score
50
max_total
50
raw_total
8
vcp_bonus
0
vol_ratio
0.9405
ret_points
8
vol_points
0
range_ratio
0.8468
volat_points
0
day_range_pct
0.0199
model_version
cursor_18_27_news_v2_160
available_bars
30
breakout_points
0
partial_history
false
pullback_points
0
breakout_vol_bonus
0
first_breakout_20d
false
return_window_days
5
first_breakout_bonus
0
breakout_quality_points
0
Risk management
level
Medium
reason
risk management score >= 6.5/10
position
score
1.6
details
atrPct
2.2261
turnoverUsdM
301.2549
liquidityPoints
0.6
volatilityPoints
1
rrPoints
1.6
stopLevels
symbol
US.EW
rr_range
1:1.0-1:2.5
risk_profile
中等
stop_loss_price
86.528
strength_details
ma_score
1
atr_score
2
rsi_score
3
macd_score
3
volume_score
1
market_adjustment
1
risk_reward_ratio
1.5
stop_loss_percent
4.5
take_profit_price
96.6214
target_multiplier
2.2
technical_strength
2.05
take_profit_percent
6.7
positionPoints
1.6
stopLossPoints
2.4
diversification
score
2
details
method
sector concentration proxy; no portfolio holdings used
sector
Health Care
concentratedSectorPenalty
0
riskRewardRatio
1.5048
stopLossPercent
4.4523
diversificationPoints
2
Calculation audit log
基本面分析總分: 2.7/5分 資金流分析總分: 15.6/20分 市場環境分析總分: 6.4/15分 催化劑分析: 2/20分 風險管理總分: 7.6/10分 技術信號分析總分: 20/30分 情緒分析: 6/10分 共振率(僅顯示不加分): 0%
Technical indicators
adx
value
78.57
atr
atr
2.016
rule
ATR / current price; lower volatility scores higher
score
6
atr_pct
2.23
cci
rule
Cursor_18.24 CCI bands
level
超買或超賣風險
score
2
value
170.95
cmf
rule
Cursor_18.24 CMF bands
level
輕微流入
score
6
value
0.1679
kdj
d
81.69
j
91.51
k
84.96
rule
Cursor_18.24 K/D cross
score
4
signal
金叉
mfi
rule
Cursor_18.24 MFI bands
level
入貨中
score
8
value
65.41
obv
rule
Cursor_18.24 recent_slope vs previous_slope
score
10
trend
強流入
value
22303278
recentSlope
1526647.8
previousSlope
-1691290
rsi
value
62.88
sar
rule
Cursor_18.24 Parabolic SAR
score
8
trend
上升
value
82.9238
position
SAR喺價下
distancePct
8.43
previousTrend
上升
ma50
value
88.0398
macd
macd
0.5197
trend
強烈看漲
signal
-0.034
histogram
0.5537
vwap
rule
Cursor_18.24 VWAP 20D consecutive close
score
10
value
86.6948
position
連續5日>VWAP
consecutiveAbove
8
volume
rule
Cursor_18.24 volume ratio
level
無力
ratio
0.94
score
4
avgVolume
3542064
currentVolume
3326578
derived
ma20
87.006
ma50
88.0398
prevClose
89.07
avgVolume10
3312708
avgVolume20
3542064
changePercent
1.67
avgVolumeForScore
3542064
ma_cross
ma20
87.006
ma50
88.0398
rule
Cursor_18.24 MA20/MA50 cross
cross
熊勢
score
0
prevMa20
86.8195
prevMa50
88.0606
spreadPct
1.17
isVolumeBreakout
false
bollinger
lower
83.6541
upper
90.3579
position
上半部
rsi_short
value
83
macd_short
macd
0
trend
中性
signal
0
histogram
0
volume_ratio
ratio
0.94
Raw calculation JSON
{
"risk": {
"level": "Medium",
"reason": "risk management score >= 6.5/10",
"position": {
"score": 1.6,
"details": {
"atrPct": 2.2261484098939928,
"turnoverUsdM": 301.25490368,
"liquidityPoints": 0.6,
"volatilityPoints": 1
}
},
"rrPoints": 1.6,
"stopLevels": {
"symbol": "US.EW",
"rr_range": "1:1.0-1:2.5",
"risk_profile": "中等",
"stop_loss_price": 86.528,
"strength_details": {
"ma_score": 1,
"atr_score": 2,
"rsi_score": 3,
"macd_score": 3,
"volume_score": 1
},
"market_adjustment": 1,
"risk_reward_ratio": 1.5,
"stop_loss_percent": 4.5,
"take_profit_price": 96.6214,
"target_multiplier": 2.2,
"technical_strength": 2.05,
"take_profit_percent": 6.7
},
"positionPoints": 1.6,
"stopLossPoints": 2.4,
"diversification": {
"score": 2,
"details": {
"method": "sector concentration proxy; no portfolio holdings used",
"sector": "Health Care",
"concentratedSectorPenalty": 0
}
},
"riskRewardRatio": 1.50484126984127,
"stopLossPercent": 4.4522968197879855,
"diversificationPoints": 2
},
"total": {
"max": 160,
"result": 68.3,
"formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
"baseScore": 60.3,
"modelVersion": "cursor_18_27_news_v2_160",
"momentum5dScore": 8
},
"market": {
"ma20": 87.006,
"ma50": 88.0398,
"close": 90.56,
"prevClose": 89.07,
"avgVolume20": 3542064,
"volumeRatio": 0.94,
"changePercent": 1.67
},
"sources": {
"catalyst": "finnhub_news_keyword_model",
"sentiment": "finnhub_news_keyword_model",
"fundamentals": "fmp_stable",
"institutional": null,
"marketContext": "twelvedata+fred"
},
"barCount": 60,
"momentum": {
"max": 50,
"result": 8,
"details": {
"ret_5d": 0.03829396927310258,
"max_score": 50,
"max_total": 50,
"raw_total": 8,
"vcp_bonus": 0,
"vol_ratio": 0.9404711150816761,
"ret_points": 8,
"vol_points": 0,
"range_ratio": 0.8468098168614459,
"volat_points": 0,
"day_range_pct": 0.019912765017667925,
"model_version": "cursor_18_27_news_v2_160",
"available_bars": 30,
"breakout_points": 0,
"partial_history": false,
"pullback_points": 0,
"breakout_vol_bonus": 0,
"first_breakout_20d": false,
"return_window_days": 5,
"first_breakout_bonus": 0,
"breakout_quality_points": 0
},
"formula": "Cursor_18.25 5D momentum v2 0-50",
"modelVersion": "cursor_18_27_news_v2_160"
},
"scoreMax": 110,
"composite": {
"max": 160,
"result": 68.3,
"formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
"weights": [
{
"raw": 2.7,
"label": "基本面",
"weight": "5/110",
"normalized": 54,
"contribution": 2.7
},
{
"raw": 15.6,
"label": "資金流",
"weight": "20/110",
"normalized": 78,
"contribution": 15.6
},
{
"raw": 6.4,
"label": "市場環境",
"weight": "15/110",
"normalized": 42.67,
"contribution": 6.4
},
{
"raw": 2,
"label": "催化劑",
"weight": "20/110",
"normalized": 10,
"contribution": 2
},
{
"raw": 7.6,
"label": "風險管理",
"weight": "10/110",
"normalized": 76,
"contribution": 7.6
},
{
"raw": 20,
"label": "技術信號",
"weight": "30/110",
"normalized": 66.67,
"contribution": 20
},
{
"raw": 6,
"label": "情緒分析",
"weight": "10/110",
"normalized": 60,
"contribution": 6
}
],
"modelVersion": "cursor_18_27_news_v2_160"
},
"momentumMax": 50,
"scoreStatus": "checked",
"standard110": {
"rating": "觀望",
"result": 60.3,
"details": [
"基本面分析總分: 2.7/5分",
"資金流分析總分: 15.6/20分",
"市場環境分析總分: 6.4/15分",
"催化劑分析: 2/20分",
"風險管理總分: 7.6/10分",
"技術信號分析總分: 20/30分",
"情緒分析: 6/10分",
"共振率(僅顯示不加分): 0%"
],
"formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
"dimensionScores": {
"催化劑": 2,
"基本面": 2.7,
"資金流": 15.6,
"市場環境": 6.4,
"情緒分析": 6,
"技術信號": 20,
"風險管理": 7.6
},
"dimensionDetails": {
"催化劑": {
"max": 20,
"grade": "較差",
"items": {
"catalyst": {
"score": 2,
"details": {
"source": "finnhub_news_keyword_model",
"articleCount": 2,
"catalystCount": 0
}
},
"catalystPoints": 2
}
},
"基本面": {
"max": 5,
"grade": "較差",
"items": {
"pbPoints": 0.2,
"pePoints": 0.2,
"epsPoints": 0,
"roePoints": 0,
"debtPoints": 0.5,
"marginPoints": 0.4,
"turnoverUsdM": 301.25490368,
"volumePoints": 0.5,
"revenuePoints": 0.4,
"dividendPoints": 0,
"marketCapPoints": 0.5
},
"source": "fmp_stable"
},
"資金流": {
"max": 20,
"grade": "良好",
"items": {
"cmfPoints": 2.4,
"mfiPoints": 3.2,
"obvPoints": 4,
"vwapPoints": 4,
"institutional": {
"score": 2,
"details": {
"source": "optional-neutral",
"warning": {
"code": "INSTITUTIONAL_DATA_OPTIONAL",
"symbol": "US.EW",
"message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
},
"optional": true,
"holderCount": null,
"holderPoints": 2,
"top10ShareRatio": null,
"concentrationPenalty": 0
}
},
"institutionPoints": 2
}
},
"市場環境": {
"max": 15,
"grade": "較差",
"items": {
"vix": {
"score": 1.8,
"details": {
"source": "twelvedata+fred",
"vixClose": 19.45
}
},
"trend": {
"score": 0.8,
"details": {
"qqq": {
"ma20": 734.0185023500001,
"ma50": 725.4347994000001,
"name": "QQQ",
"close": 712.20001,
"points": 0.4
},
"spy": {
"ma20": 770.1384979000001,
"ma50": 767.5889950999999,
"name": "SPY",
"close": 765.37,
"points": 0.4
},
"source": "twelvedata+fred"
}
},
"atrPct": 2.2261484098939928,
"atrPoints": 3,
"cciPoints": 0.8,
"vixPoints": 1.8,
"marketTrendPoints": 0.8
}
},
"情緒分析": {
"max": 10,
"grade": "一般",
"items": {
"sentiment": {
"score": 6,
"details": {
"source": "finnhub_news_keyword_model",
"articleCount": 2,
"negativeHits": 0,
"positiveHits": 1,
"sentimentScoreRaw": 1.2
}
},
"sentimentData": {
"raw": [
{
"id": 143132433,
"url": "https://finnhub.io/api/news?id=b913cc1f116b22cc2be45e9b6bd9d7b38f17ecce5afdecf6450e60f48867bf84",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "EW",
"summary": "Edwards Lifesciences reported past FDA approvals for its PASCAL Precision system for tricuspid valve repair and PASCAL Ace with Capture Clarity for degenerative mitral TEER, giving the business a broader U.S. transcatheter repair toolkit for patients who are not good candidates for open heart surgery. The combination of tricuspid and mitral TEER approvals makes Edwards Lifesciences the only supplier offering both repair and replacement transcatheter options across these valves in the U.S.,...",
"category": "company",
"datetime": 1792754284,
"headline": "Does Valve Repair Approval Change The Bull Case For Edwards Lifesciences (EW)?"
},
{
"id": 143100621,
"url": "https://finnhub.io/api/news?id=a8698f0719f543a45a3043e24bc1b0a6f9596a76ec9c66d43eab7060c8670246",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "EW",
"summary": "Edwards Lifesciences' TMTT and TAVR growth, strong clinical evidence and solid balance sheet support expansion, but tariffs and currency headwinds threaten margins.",
"category": "company",
"datetime": 1792669680,
"headline": "Is This the Right Time to Hold EW Stock in Your Portfolio?"
}
],
"raw_source": [
{
"id": 143135911,
"url": "https://finnhub.io/api/news?id=789c5f64f3f2cf7881b4b07392f83e9f63dfedf383c1ea91818187027101ec47",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "EW",
"summary": "Inspire Medical Systems gains 47.8% in three months as improved reimbursement clarity, an earnings beat, $30 million in annual savings and new CPT codes boost recovery prospects.",
"category": "company",
"datetime": 1792766220,
"headline": "INSP Stock Gains 47.8% in Three Months: What's Driving the Rally?"
},
{
"id": 143132433,
"url": "https://finnhub.io/api/news?id=b913cc1f116b22cc2be45e9b6bd9d7b38f17ecce5afdecf6450e60f48867bf84",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "EW",
"summary": "Edwards Lifesciences reported past FDA approvals for its PASCAL Precision system for tricuspid valve repair and PASCAL Ace with Capture Clarity for degenerative mitral TEER, giving the business a broader U.S. transcatheter repair toolkit for patients who are not good candidates for open heart surgery. The combination of tricuspid and mitral TEER approvals makes Edwards Lifesciences the only supplier offering both repair and replacement transcatheter options across these valves in the U.S.,...",
"category": "company",
"datetime": 1792754284,
"headline": "Does Valve Repair Approval Change The Bull Case For Edwards Lifesciences (EW)?"
},
{
"id": 143136778,
"url": "https://finnhub.io/api/news?id=5a5d111056252b2999b0ad4b505d9e30cec05621715a58d9d8440adabcce4679",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "EW",
"summary": "Edwards’ approval should “strengthen the company’s position in the large and underpenetrated transcatheter tricuspid market,” analysts said.",
"category": "company",
"datetime": 1792750806,
"headline": "Edwards wins FDA approval for tricuspid valve repair device"
},
{
"id": 143103804,
"url": "https://finnhub.io/api/news?id=62fd12e5080b12b6263d31d607a9f1b4d07b54f3d1d98dbe99a2fb7960637686",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "EW",
"summary": "DaVita's 55.6% stock rally reflects stronger operating execution, improving treatment volumes and value-based kidney care gains despite reimbursement pressures.",
"category": "company",
"datetime": 1792690680,
"headline": "DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally?"
},
{
"id": 143103803,
"url": "https://finnhub.io/api/news?id=64e91c8c6fe34a2c1b6d7ffac246833155002d30dbbbee5bbf17bcba5d08f536",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "EW",
"summary": "BD's 25.5% rally reflects stronger execution, portfolio reshaping, product innovation and U.S. manufacturing investments despite tariffs and cost pressures.",
"category": "company",
"datetime": 1792689660,
"headline": "BDX Stock Gains 25.5% in Six Months: What's Behind the Rally?"
},
{
"id": 143100621,
"url": "https://finnhub.io/api/news?id=a8698f0719f543a45a3043e24bc1b0a6f9596a76ec9c66d43eab7060c8670246",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "EW",
"summary": "Edwards Lifesciences' TMTT and TAVR growth, strong clinical evidence and solid balance sheet support expansion, but tariffs and currency headwinds threaten margins.",
"category": "company",
"datetime": 1792669680,
"headline": "Is This the Right Time to Hold EW Stock in Your Portfolio?"
},
{
"id": 143094387,
"url": "https://finnhub.io/api/news?id=b2c85aa8df922e4873506e30b09daeb9bd72bff0ea48f981feb94a865d6e34f3",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "EW",
"summary": "The PASCAL Precision device is indicated to treat individuals with symptomatic severe tricuspid regurgitation.",
"category": "company",
"datetime": 1792660520,
"headline": "Edwards secures FDA approval for tricuspid valve repair system"
},
{
"id": 143067817,
"url": "https://finnhub.io/api/news?id=b4575036babe3ca17c3d9b9b280784523ba14d92717883c8b9ffb333608060fd",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "EW",
"summary": "IRVINE, Calif., October 21, 2026--Edwards Lifesciences Corporation (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved its PASCAL Precision system for tricuspid valve repair. The system is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation (TR) despite optimal medical therapy who are deemed at intermediate or greater risk for surgery and deemed appropriate for transcatheter edge-to-edge tr",
"category": "company",
"datetime": 1792587600,
"headline": "FDA Approval of Edwards Lifesciences’ PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease"
},
{
"id": 143067541,
"url": "https://finnhub.io/api/news?id=81838d297dff31d72c83688080f0c7fe609014e55d3a8995b53e4433356df155",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "EW",
"summary": "ISRG's Q3 2026 earnings beat estimates as strong system placements, rising procedure volumes and improving margins fuel double-digit revenue growth.",
"category": "company",
"datetime": 1792585980,
"headline": "Intuitive Surgical's Q3 Earnings Beat Estimates on Strong System Sales"
},
{
"id": 143067057,
"url": "https://finnhub.io/api/news?id=c52e0234621653156fb737978b4b17fc182b84f9ed2c5c3bcd798f931671d143",
"image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_2.jpg?width=2048&height=1536",
"source": "Benzinga",
"related": "EW",
"summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
"category": "company",
"datetime": 1792503310,
"headline": "9 Health Care Stocks Whale Activity In Today’s Session"
},
{
"id": 142950181,
"url": "https://finnhub.io/api/news?id=96549fc3169af14a5b37e1838856ce6d4ea231da47ab79fb2b1b643ba4673a05",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "EW",
"summary": "The U.S. Food and Drug Administration (FDA) issued a high-risk early alert after Edwards Lifesciences Corp. (NYSE:EW) recalled specific lots of its Commander M delivery systems due to reports of balloons bursting during procedures, resulting in one death and a serious injury. Recall Of Commander M Delivery Systems The delivery systems help implant a replacement mitral heart valve through blood vessels, bypassing the need for open-chest surgery. However, the company received three distinct report",
"category": "company",
"datetime": 1792163582,
"headline": "FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death"
},
{
"id": 142945843,
"url": "https://finnhub.io/api/news?id=efc985c8849482b1c5cb63a903feab7a147146983249315764c2b32ff17b12da",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "EW",
"summary": "An issue with the delivery component of Edwards’ SAPIEN M3 TMVR system has been associated with one patient death and one serious injury as of 5 October.",
"category": "company",
"datetime": 1792151246,
"headline": "Edwards’ SAPIEN M3 delivery system linked to patient death in FDA alert"
},
{
"id": 142947552,
"url": "https://finnhub.io/api/news?id=cce961828583081443d280e38e71db1b045f33b20765ffc7c43f7023022e5860",
"image": "",
"source": "Benzinga",
"related": "EW",
"summary": "https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-transcatheter-mitral-valve-delivery-system-issue-edwards-lifesciences ",
"category": "company",
"datetime": 1792122647,
"headline": "Reported Earlier, Edwards Lifesciences Tells Customers To Remove Four Lots Of Commander M Delivery Systems For SAPIEN M3; FDA Flags Potentially High-Risk Issue"
},
{
"id": 142882630,
"url": "https://finnhub.io/api/news?id=5e4289c0c9b96dfa1e95a00694f6be0915f8672c2b831308bed3a3fce09f0551",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "EW",
"summary": "With the US population aging rapidly, three healthcare ETFs offer exposure to companies developing treatments, drugs and medical devices for age-related conditions.",
"category": "company",
"datetime": 1791979740,
"headline": "Bet on These Healthcare ETFs to Benefit From the Aging US Population"
},
{
"id": 142821843,
"url": "https://finnhub.io/api/news?id=5b892fbff9720a6bd56b824deb05c3dc8dcd697cd77783988b10fb0eaab315fb",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "EW",
"summary": "Edwards Lifesciences is set to report its Q3 earnings next month, with analysts expecting single-digit year-over-year EPS growth.",
"category": "company",
"datetime": 1791795397,
"headline": "Edwards Lifesciences Earnings Preview: What to Expect"
},
{
"id": 142730419,
"url": "https://finnhub.io/api/news?id=5741fde32d2d428cfb091510e2b9dc970e9a9cdc9798a0a9de13df26fb600389",
"image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
"source": "ChartMill",
"related": "EW",
"summary": "Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.",
"category": "company",
"datetime": 1791477301,
"headline": "Stay informed with the top movers within the S&P500 index on Thursday."
},
{
"id": 142703057,
"url": "https://finnhub.io/api/news?id=cbb9c770540f123bf7f8169895da328689f42faa5286fda4eeaa46990dd6c523",
"image": "",
"source": "Fintel",
"related": "EW",
"summary": "",
"category": "company",
"datetime": 1791417130,
"headline": "Barclays Initiates Coverage of Edwards Lifesciences at Overweight"
},
{
"id": 142699429,
"url": "https://finnhub.io/api/news?id=c7662009b9ace98cff37eb649fd5c094fe1d8023fc1a1ff779048499c9832520",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "EW",
"summary": "Intuitive Surgical SP platform is gaining momentum as procedures, utilization and placements rise, with expanding indications and global adoption fueling growth.",
"category": "company",
"datetime": 1791394260,
"headline": "Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise?"
},
{
"id": 140420211,
"url": "https://finnhub.io/api/news?id=c9045c53ac19ad80d94a07c2e8320fa134ac76c18ad5824d79898864952688d5",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "EW",
"summary": "Intel downgraded, Marvell upgraded: Wall Street's top analyst calls",
"category": "company",
"datetime": 1791381613,
"headline": "Intel downgraded, Marvell upgraded: Wall Street's top analyst calls"
},
{
"id": 142689571,
"url": "https://finnhub.io/api/news?id=7328d68ff960ea6cd6cc1d7e84ad93210c84e804ca09c005e1de805c1458a6df",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "EW",
"summary": "IRVINE, Calif., October 07, 2026--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended Sept. 30, 2026 after the market closes on Wednesday, Nov. 4, and will host a conference call at 5:00 p.m. ET that day to discuss those results.",
"category": "company",
"datetime": 1791367200,
"headline": "Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026"
},
{
"id": 142696722,
"url": "https://finnhub.io/api/news?id=b571dd0f7ba78a624d470fa3b3093c847514e128ce54822d2c1d0f3490f79271",
"image": "",
"source": "Benzinga",
"related": "EW",
"summary": "Barclays analyst Christopher Pasquale initiates coverage on Edwards Lifesciences (NYSE:EW) with a Overweight rating and announces Price Target of $110.",
"category": "company",
"datetime": 1791362408,
"headline": "Barclays Initiates Coverage On Edwards Lifesciences with Overweight Rating, Announces Price Target of $110"
},
{
"id": 142632289,
"url": "https://finnhub.io/api/news?id=5e79a351c69253cee95dc15b7a09a3b5363e19ef80d37e125eab80d72c621996",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "EW",
"summary": "IRVINE, Calif., October 05, 2026--Edwards Lifesciences (NYSE: EW) today announced that it will host an investor event in conjunction with the TCT annual scientific symposium in San Diego on Monday, Nov. 2, from 5:00 to 6:00 PM Pacific Time. The meeting will include a live Q&A session with physicians and members of the Edwards management team.",
"category": "company",
"datetime": 1791194400,
"headline": "Edwards Lifesciences to Host Investor Event in Conjunction With TCT"
},
{
"id": 142614627,
"url": "https://finnhub.io/api/news?id=8655f8ec1bb477449776d78501af9ab82fe6b743d6ab33f1f8d7997fe0bbe8ef",
"image": "https://cdn.benzinga.com/files/images/story/2026/10/02/Doctors--Tablet-And-People-With-Discussi.jpg?width=2048&height=1536",
"source": "Benzinga",
"related": "EW",
"summary": "Edwards Lifesciences earned FDA approval for its AUTUS pediatric heart valve, designed to expand as young patients grow.",
"category": "company",
"datetime": 1790937962,
"headline": "Edwards Lifesciences Secures FDA Approval for First Expandable Pediatric Heart Valve"
},
{
"id": 142589114,
"url": "https://finnhub.io/api/news?id=80eebecc20b73e3685f3c3092f41f338a5253af972377b06c0dc5ce304802ac8",
"image": "https://cdn.benzinga.com/files/images/story/2026/10/02/Bangkok--Thailand---July-2--2017nike-Cla.jpg?width=2048&height=1536",
"source": "Benzinga",
"related": "EW",
"summary": "Nike falls on weak revenue; Synaptics jumps on $123 ON deal; AsiaStrategy surges on tokenization pact; Mangoceuticals drops.",
"category": "company",
"datetime": 1790914563,
"headline": "Nike, Synaptics And 3 Stocks To Watch Heading Into Friday"
},
{
"id": 142563009,
"url": "https://finnhub.io/api/news?id=b0ab83642594294ce72c45514fe4296905c2602deb7307b9dddd9eaf37adf90a",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "EW",
"summary": "IRVINE, Calif., October 01, 2026--Edwards Lifesciences (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease who require pulmonary valve replacement.",
"category": "company",
"datetime": 1790886360,
"headline": "Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients"
},
{
"id": 142590120,
"url": "https://finnhub.io/api/news?id=17619dfabefb34c722fa720a4545f003a4542ab1a2e12bc371a4dd0e88326aff",
"image": "",
"source": "Benzinga",
"related": "EW",
"summary": "Edwards Lifesciences (NYSE:EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with",
"category": "company",
"datetime": 1790872027,
"headline": "Edwards Lifesciences Says FDA Approves AUTUS Size-Adjustable Valve, Surgical Pulmonary Valve Designed For Pediatric Patients With Congenital Heart Disease"
}
],
"data_source": "finnhub_news_keyword_model",
"article_count": 2,
"negative_hits": 0,
"positive_hits": 1,
"recomputed_at_score": true,
"sentiment_score_raw": 1.2,
"source_article_count": 26,
"discarded_article_count": 24
},
"sentimentPoints": 6
}
},
"技術信號": {
"max": 30,
"raw": 20,
"grade": "一般",
"items": {
"bbPoints": 3,
"adxPoints": 3,
"sarPoints": 2.4000000000000004,
"vcpPoints": 0.9,
"macdPoints": 4,
"vcpPayload": {
"vcp_pass": false,
"vcp_score": 0.9,
"vcp_reason": "站上MA50；升放量(近10日2日)；Ready=N；Confirm=Y",
"vcp_metrics": {
"up_days": 6,
"vol_ref": 3620926.6666666665,
"down_days": 3,
"vcp_ready": false,
"above_ma50": true,
"avg_vol_10": 3312480,
"avg_vol_20": 3537140,
"avg_vol_30": 3620926.6666666665,
"range_pct_10": 0.07177565150176686,
"range_pct_20": 0.09518554549469961,
"range_pct_30": 0.09518554549469961,
"up_expand_ok": true,
"lookback_used": 59,
"near_20d_high": true,
"contraction_ok": false,
"down_shrink_ok": false,
"up_expand_days": 2,
"breakout_20d_ok": false,
"vol_ratio_10_30": 0.914815544455471,
"dist_to_20d_high": 0.005381691201042591,
"down_shrink_days": 1,
"breakout_level_20d": 91.050003,
"vcp_breakout_confirm": true,
"contraction_ratio_10_30": 0.7540604104198119
},
"vcp_name_en": "Volatility Contraction Pattern",
"vcp_name_zh": "波動收縮形態",
"vol_contraction": false
},
"kdjAdxPoints": 0.7,
"rsiKdjPoints": 4,
"volumeWeight": 2,
"maCrossPoints": 0,
"shortRsiPoints": 0.8,
"shortMacdPoints": 0.4,
"volConfirmPoints": 0,
"volumePointsTechnical": 0.8
}
},
"風險管理": {
"max": 10,
"grade": "良好",
"items": {
"position": {
"score": 1.6,
"details": {
"atrPct": 2.2261484098939928,
"turnoverUsdM": 301.25490368,
"liquidityPoints": 0.6,
"volatilityPoints": 1
}
},
"rrPoints": 1.6,
"stopLevels": {
"symbol": "US.EW",
"rr_range": "1:1.0-1:2.5",
"risk_profile": "中等",
"stop_loss_price": 86.528,
"strength_details": {
"ma_score": 1,
"atr_score": 2,
"rsi_score": 3,
"macd_score": 3,
"volume_score": 1
},
"market_adjustment": 1,
"risk_reward_ratio": 1.5,
"stop_loss_percent": 4.5,
"take_profit_price": 96.6214,
"target_multiplier": 2.2,
"technical_strength": 2.05,
"take_profit_percent": 6.7
},
"positionPoints": 1.6,
"stopLossPoints": 2.4,
"diversification": {
"score": 2,
"details": {
"method": "sector concentration proxy; no portfolio holdings used",
"sector": "Health Care",
"concentratedSectorPenalty": 0
}
},
"riskRewardRatio": 1.50484126984127,
"stopLossPercent": 4.4522968197879855,
"diversificationPoints": 2
}
}
}
},
"modelVersion": "cursor_18_27_news_v2_160",
"providerErrors": [],
"rankingScoreMax": 160,
"dataCompleteness": {
"complete": true,
"missingFields": [],
"optionalInputs": [
"institutionalData"
],
"requiredInputs": [
"fundamentals",
"marketContext.VIX",
"marketContext.SPY",
"marketContext.QQQ",
"catalystData",
"sentimentData",
"ATR",
"sector"
],
"optionalInputWarnings": []
},
"technicalIndicators": {
"adx": 78.57,
"atr": {
"atr": 2.016,
"rule": "ATR / current price; lower volatility scores higher",
"score": 6,
"atr_pct": 2.23
},
"cci": {
"rule": "Cursor_18.24 CCI bands",
"level": "超買或超賣風險",
"score": 2,
"value": 170.95
},
"cmf": {
"rule": "Cursor_18.24 CMF bands",
"level": "輕微流入",
"score": 6,
"value": 0.1679
},
"kdj": {
"d": 81.69,
"j": 91.51,
"k": 84.96,
"rule": "Cursor_18.24 K/D cross",
"score": 4,
"signal": "金叉"
},
"mfi": {
"rule": "Cursor_18.24 MFI bands",
"level": "入貨中",
"score": 8,
"value": 65.41
},
"obv": {
"rule": "Cursor_18.24 recent_slope vs previous_slope",
"score": 10,
"trend": "強流入",
"value": 22303278,
"recentSlope": 1526647.8,
"previousSlope": -1691290
},
"rsi": 62.88,
"sar": {
"rule": "Cursor_18.24 Parabolic SAR",
"score": 8,
"trend": "上升",
"value": 82.9238,
"position": "SAR喺價下",
"distancePct": 8.43,
"previousTrend": "上升"
},
"ma50": 88.0398,
"macd": {
"macd": 0.5197219755279292,
"trend": "強烈看漲",
"signal": -0.03399683913886334,
"histogram": 0.5537188146667925
},
"vwap": {
"rule": "Cursor_18.24 VWAP 20D consecutive close",
"score": 10,
"value": 86.6948,
"position": "連續5日>VWAP",
"consecutiveAbove": 8
},
"volume": {
"rule": "Cursor_18.24 volume ratio",
"level": "無力",
"ratio": 0.94,
"score": 4,
"avgVolume": 3542064,
"currentVolume": 3326578
},
"derived": {
"ma20": 87.006,
"ma50": 88.0398,
"prevClose": 89.07,
"avgVolume10": 3312708,
"avgVolume20": 3542064,
"changePercent": 1.67,
"avgVolumeForScore": 3542064
},
"ma_cross": {
"ma20": 87.006,
"ma50": 88.0398,
"rule": "Cursor_18.24 MA20/MA50 cross",
"cross": "熊勢",
"score": 0,
"prevMa20": 86.8195,
"prevMa50": 88.0606,
"spreadPct": 1.17,
"isVolumeBreakout": false
},
"bollinger": {
"lower": 83.6541,
"upper": 90.3579,
"position": "上半部"
},
"rsi_short": 83,
"macd_short": {
"macd": 0,
"trend": "中性",
"signal": 0,
"histogram": 0
},
"volume_ratio": {
"ratio": 0.94
}
}
}
Raw metrics JSON
{
"close": 90.56,
"volume": 3326578,
"changePercent": 1.67
}
Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.